The hospice and palliative care sector is highly fragmented, Medicare-reimbursed, and recession-resistant — making it one of the most compelling roll-up opportunities in the lower middle market for operators and PE-backed platforms alike.
Find Hospice & Palliative Care Acquisition TargetsThe hospice and palliative care industry is a $22–25 billion Medicare-dominated segment serving terminally ill patients and their families through comfort-focused, home-based end-of-life care. Reimbursed almost entirely through the Medicare Hospice Benefit, the sector is driven by demographic tailwinds — particularly the aging Baby Boomer population — alongside rising chronic disease prevalence and a broad cultural shift toward home-based care over hospitalization. The industry is highly fragmented, with thousands of independent, founder-operated agencies generating $1M–$5M in annual revenue, many owned by nurses, physicians, or social workers who built their agencies over 10–20 years and are now approaching retirement. This fragmentation, combined with durable Medicare reimbursement, meaningful regulatory barriers to entry, and deep referral-based moats, creates a textbook environment for a disciplined roll-up acquisition strategy.
Hospice and palliative care offers roll-up acquirers a rare combination of structural advantages that are difficult to replicate in other healthcare segments. Medicare certification and state licensure create high barriers to entry, protecting existing operators from new competition. Referral relationships with hospitals, SNFs, and physician practices are trust-based and take years to develop, making acquired census books genuinely sticky. The sector is recession-resistant — end-of-life care demand is non-discretionary and demographically inevitable — and reimbursement is federally backstopped through CMS rather than subject to commercial payer negotiation cycles. EBITDA margins of 15–30% are achievable for well-run agencies, and the absence of professional management infrastructure in most founder-operated targets creates immediate post-acquisition value creation opportunities through operational standardization, centralized billing, and shared clinical leadership. For PE-backed platforms or experienced healthcare operators, acquiring four to eight regional hospice agencies and integrating them under a unified compliance, billing, and clinical leadership structure can produce a platform valued at 8–12x EBITDA at exit — meaningfully above the 4–7x entry multiples paid for individual agencies.
The hospice roll-up thesis is built on four durable pillars. First, fragmentation: the majority of U.S. hospice agencies are independently owned and operated, most generating under $5M in revenue, with founding operators reaching retirement age and facing increasing regulatory complexity they lack the infrastructure to manage. Second, reimbursement stability: Medicare hospice reimbursement rates are updated annually by CMS and have historically provided predictable, inflation-adjusted revenue growth tied to ADC rather than volume-based fee schedules, making cash flow modeling straightforward. Third, multiple arbitrage: independent agencies trade at 4–7x EBITDA while regional platforms with diversified census, clean compliance records, and professional management consistently command 8–12x EBITDA at institutional exit, creating 300–500 basis points of multiple expansion per acquired unit. Fourth, operational leverage: centralized functions including Medicare billing, QAPI oversight, HR and credentialing, compliance monitoring, and EMR infrastructure can be built once and spread across multiple acquired agencies, compressing costs and standardizing quality across the platform. The primary execution risks — Medicare CHOW complexity, compliance liability carryover, and clinical staff retention — are manageable with the right legal, clinical, and operational diligence frameworks in place before each acquisition closes.
$1M–$5M
Revenue Range
$300K–$1.5M
EBITDA Range
Define Your Platform Thesis and Target Geography
Before approaching any target, establish a clear platform thesis: which geographic markets do you want to dominate, what patient census size constitutes a minimum viable acquisition, and what compliance profile is acceptable. Hospice is a locally referral-driven business — your platform will be built market by market, not nationally. Identify two to three anchor markets where you can acquire an initial agency with ADC of 60 or more, Medicare certification in good standing, and a referral network you can build upon. Map competitor density, CON regulations, and CMS survey history in each target market before initiating outreach.
Key focus: Market selection, CON environment analysis, minimum viable ADC thresholds, and platform geographic scope definition
Source and Qualify Target Agencies
Most independent hospice agencies are not formally listed for sale. Effective sourcing requires direct outreach to founders via state hospice association directories, CMS CASPER data, and healthcare broker networks with hospice transaction experience. Screen targets for Medicare certification status, ADC trends, payer mix, and any visible compliance flags including recent survey deficiencies or CMS enforcement actions visible in public data. Prioritize founder-operators approaching retirement who have not yet engaged an advisor — these conversations often yield better deal terms and more cooperative diligence processes than auction-style broker processes.
Key focus: Off-market outreach, CMS CASPER screening, founder retirement motivation identification, and broker network engagement
Conduct Hospice-Specific Due Diligence
Hospice due diligence requires a healthcare-specialized team with deep Medicare billing and compliance expertise. Priority areas include: Medicare cost reports and cap calculations for the trailing three years to identify overpayment exposure or cap proximity; clinical compliance records including QAPI documentation, IDT meeting minutes, and employee licensure files; referral source concentration analysis with anti-kickback statute review of any written agreements; ADC trend analysis, live discharge rates, and length-of-stay data as leading indicators of clinical integrity; and staff turnover rates with employment agreements for the Director of Nursing, Administrator, and key RN staff. Engage a healthcare M&A attorney experienced in Medicare CHOW before LOI execution.
Key focus: Medicare cap exposure, RAC audit liability, referral source AKS compliance, clinical staff retention risk, and CHOW legal preparation
Structure the Deal to Manage Compliance and Census Risk
Most hospice acquisitions in the lower middle market use asset purchase structures with Medicare provider agreement novation, allowing the buyer to assume the existing provider number while limiting historical liability exposure. Include a 10–20% seller note or earnout tied to census retention at 90 and 180 days post-close to align seller incentives with patient and referral continuity. Escrow holdbacks of 10–15% of purchase price for a period of 12–18 months provide a financial buffer against undisclosed Medicare overpayment demands or post-close compliance findings. For sellers with clean compliance records and strong referral relationships, an equity rollover of 15–30% can accelerate integration and preserve referral source trust during the ownership transition.
Key focus: Asset vs. stock purchase analysis, Medicare CHOW novation, earnout tied to ADC retention, escrow holdback structuring, and equity rollover mechanics
Execute CHOW and Transition Clinical Operations
The Medicare Change of Ownership process is the most operationally critical phase of a hospice acquisition. File CHOW documentation with CMS immediately upon closing using CMS-855A and coordinate with the MAC to ensure uninterrupted billing during the transition period. Retain the existing Director of Nursing and Administrator through a minimum 90-day transition employment agreement. Maintain existing referral source relationships by having the seller personally introduce the new ownership team to hospital discharge planners, SNF social workers, and referring physicians within the first 30 days. Preserve existing EMR data, care plans, and IDT documentation to ensure clinical continuity for patients currently on service.
Key focus: CMS-855A CHOW filing, MAC coordination, billing continuity, referral source relationship transition, and clinical staff retention agreements
Integrate and Standardize Across the Platform
After the first acquisition is stabilized — typically 90–180 days post-close — begin centralizing back-office functions across acquired agencies. Centralize Medicare billing and compliance monitoring under a single revenue cycle management function with hospice billing expertise. Implement a unified EMR platform across all agencies to enable enterprise-wide QAPI reporting and CMS survey preparation. Consolidate HR and credentialing processes to reduce administrative burden on clinical leadership and improve staff recruitment and retention. Standardize clinical protocols, IDT documentation, and care planning processes to reduce live discharge rates and improve length-of-stay metrics across the portfolio — both of which directly improve EBITDA and valuation at exit.
Key focus: Centralized billing and compliance infrastructure, EMR standardization, HR consolidation, clinical protocol harmonization, and QAPI enterprise reporting
Centralized Medicare Billing and Revenue Cycle Management
Independent hospice agencies frequently leave revenue on the table through inconsistent billing practices, undercoded diagnoses, and missed continuous home care and general inpatient care billing opportunities. Centralizing billing under a hospice-experienced RCM team across the platform can improve net revenue per patient day by 5–12% while simultaneously reducing Medicare overpayment exposure through systematic cap monitoring and claims auditing.
Clinical Protocol Standardization to Improve Length-of-Stay and Reduce Live Discharges
Live discharge rates above 20% and short median lengths of stay are red flags for both CMS and institutional buyers. Implementing standardized eligibility documentation protocols, physician certification workflows, and IDT review processes across acquired agencies reduces premature live discharges and improves length-of-stay metrics — directly increasing ADC and EBITDA without adding new admissions.
Diversified Referral Network Expansion
Most acquired agencies depend heavily on one to three referral relationships. Building a platform-wide business development function targeting hospital discharge planners, SNF social workers, and palliative care physicians across all service territories diversifies the referral base, reduces census volatility, and increases the defensibility of the platform's revenue at exit.
Shared Clinical Leadership and Workforce Infrastructure
Recruiting a platform-level Chief Nursing Officer or VP of Clinical Operations allows individual agency Directors of Nursing to focus on direct care supervision rather than administrative compliance. Shared credentialing, float pool nursing staff, and platform-wide recruitment resources reduce per-agency labor costs and improve clinical staffing stability — one of the most significant operational risks in hospice acquisitions.
ACHC or CHAP Accreditation Across the Portfolio
Pursuing ACHC or CHAP accreditation for each acquired agency — or maintaining existing accreditation through ownership transitions — signals clinical quality to referral sources, reduces CMS survey deficiency risk, and is increasingly expected by institutional buyers at exit. Accreditation achieved at the platform level through shared preparation resources costs less per agency than independent pursuit and can be used as a competitive differentiator in referral source marketing.
Add-On Acquisition Synergies in Contiguous Markets
Each acquired agency creates a geographic beachhead from which to pursue adjacent market acquisitions. Shared back-office infrastructure, clinical leadership, and referral source networks reduce the cost and complexity of each successive acquisition. By the fourth or fifth acquisition, platform-level EBITDA margins often exceed 25–30%, meaningfully above the 15–20% margins typical of individual agencies, creating the multiple expansion necessary for a compelling institutional exit.
A well-constructed hospice roll-up platform with four to eight acquired agencies, $8M–$20M in combined revenue, and $2M–$5M in normalized EBITDA will attract institutional exit interest from three distinct buyer categories. First, large national hospice and home health chains including VITAS, Amedisys, LHC Group successors, and Enhabit are active acquirers of regional platforms with clean compliance records and geographic density, typically paying 9–12x EBITDA for platforms with ADC above 400. Second, larger private equity-backed hospice platforms seeking geographic expansion will pay 8–11x EBITDA for tuck-in regional platforms that accelerate their own roll-up timelines. Third, sovereign wealth funds and large healthcare-focused PE sponsors seeking established platforms with institutional management infrastructure and diversified referral networks have become active in the hospice sector as its demographic tailwinds and reimbursement stability become more broadly recognized. To maximize exit valuation, platform operators should target a minimum trailing twelve-month EBITDA of $2.5M, clean CMS survey history across all acquired agencies, no active OIG or RAC audit exposure, ADC trending upward across the portfolio, and a management team that can operate independently of any single founding operator. Engaging a healthcare-specialized investment bank rather than a generalist M&A advisor 18–24 months before a planned exit allows time to resolve any compliance gaps, optimize financial presentation, and run a competitive process among qualified institutional buyers.
Find Hospice & Palliative Care Roll-Up Targets
Signal-scored acquisition targets matched to your roll-up criteria.
Independent hospice agencies with $1M–$5M in revenue and $300K–$1.5M in EBITDA typically trade at 4–7x EBITDA, depending on ADC size, compliance history, referral source diversification, and Medicare cap position. Agencies with clean CMS survey records, growing census, and tenured clinical leadership command multiples at the higher end of that range. Regional platforms assembled through roll-up acquisitions with $2M or more in combined EBITDA consistently attract exit multiples of 8–12x from institutional buyers, making multiple arbitrage one of the primary value creation mechanisms in a hospice roll-up strategy.
The Medicare CHOW process is the CMS-required procedure for transferring a hospice provider agreement — and its associated Medicare billing privileges — from a seller to a buyer. It is initiated by filing CMS Form 855A with the Medicare Administrative Contractor (MAC) upon closing. In an asset purchase, the buyer assumes the existing provider number through novation rather than applying for a new certification, which preserves billing continuity and avoids the 6–12 month delay associated with new Medicare certification. The CHOW process is critical because any interruption in Medicare billing during the transition period directly impairs ADC revenue. Engaging a healthcare M&A attorney with CHOW experience before LOI execution is essential to ensure the transaction structure supports a clean provider agreement transfer.
The Medicare hospice cap limits the total Medicare reimbursement a hospice provider can receive in a cap year — for 2024, approximately $34,465 per beneficiary. If a hospice's total Medicare payments in a cap year exceed its cap calculation, CMS requires repayment of the overage. When evaluating a target, request Medicare cost reports for the trailing three cap years and calculate the agency's cap utilization rate. Agencies operating above 90% of their cap limit carry meaningful overpayment risk and may signal aggressive length-of-stay management or eligibility documentation issues. A healthcare billing consultant with hospice cost report experience should review cap calculations independently as part of financial due diligence.
Clinical staff retention begins before closing. Offer key personnel — particularly the Director of Nursing, Administrator, and senior RNs — written retention agreements with 90–180 day stay bonuses tied to continued employment post-close. Communicate transparently with the full clinical team about ownership transition, organizational continuity, and any planned operational changes. For referral sources, have the selling owner personally introduce the new ownership team to hospital discharge planners, SNF social workers, and referring physicians within the first 30 days post-close. Referral relationships are built on trust and personal relationships — preserving those introductions is far more effective than any marketing initiative initiated by new ownership alone.
The three highest-priority compliance risks in hospice due diligence are: first, Medicare cap exposure and billing integrity, including any RAC audit findings, overpayment demands, or MAC probe reviews in the trailing three years; second, eligibility documentation quality, meaning whether physician certifications, clinical narratives, and IDT documentation support the terminal prognosis for patients on service — poor documentation is the most common trigger for CMS enforcement actions; and third, referral source relationships and anti-kickback statute compliance, including any written agreements with hospitals, SNFs, or physicians that could be construed as improper remuneration for referrals. Engage a healthcare compliance attorney to review all referral agreements and billing records before LOI execution.
Yes, hospice agency acquisitions are eligible for SBA 7(a) financing when structured as asset purchases by individual buyers or small operating companies. SBA loans can finance up to $5M of the purchase price with 10-year terms and competitive interest rates, making them well-suited for acquisitions in the $1M–$4M total consideration range. Lenders will require three years of business tax returns, interim financial statements, Medicare cost reports, and evidence of a clean compliance record. The CHOW process must be coordinated carefully with SBA loan closing timelines to ensure billing continuity. Note that PE-backed platforms typically use non-SBA acquisition financing given ownership structure requirements, but individual owner-operators and first-time hospice buyers frequently use SBA 7(a) loans as their primary acquisition financing vehicle.
More Hospice & Palliative Care Guides
More Roll-Up Strategy Guides
Build your platform from the best Hospice & Palliative Care operators on the market — free to start.
Create your free accountNo credit card required
For Buyers
For Sellers